Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis

Exclusion Criteria

• •Previous participation in another clinical study within the preceding 12 weeks
• •Tracheostomy or assisted ventilation of any type during the preceding three months
• •Gastrostomy
• •Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS
• •Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment
• •Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine.
• •Patients on analgesics with serotoninergic properties such as meperidine, tramadol, methadone and propoxyphene.
• •Patients on serotonin reuptake inhibitors (SSRIs). This includes fluoxetine or fluvoxamine.
• •Patients on dextromethorphan, St. John's wort, cyclobenzaprine or other MAO inhibitors (selective or non-selective)
• •Patients taking Antidepressants
• •Confirmed hepatic insufficiency or abnormal liver function (ASAT and/or ALAT greater than 3 times the upper limit of the normal range)
• •Renal insufficiency (serum creatinine more than 2.26 mg/dL)
• •Evidence of major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms
• •Known hypersensitivity to any component of the study drug
• •Liable to be not cooperative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the case of emergency
• •Female with childbearing potential, if no adequate contraceptive measures are used
• •Pregnancy or breast-feeding females